New Zealand markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.45+0.14 (+0.21%)
At close: 04:00PM EDT
65.90 +0.45 (+0.69%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close65.31
Open64.72
Bid0.00 x 900
Ask0.00 x 1100
Day's range64.38 - 65.96
52-week range57.17 - 74.12
Volume5,802,318
Avg. volume6,943,687
Market cap82.033B
Beta (5Y monthly)0.33
PE ratio (TTM)20.02
EPS (TTM)3.27
Earnings date26 Oct 2022 - 31 Oct 2022
Forward dividend & yield2.92 (4.47%)
Ex-dividend date14 Sept 2022
1y target est71.40
  • Zacks

    Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

    Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.

  • Business Wire

    Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

    SANTA MONICA, Calif., October 03, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au

  • Motley Fool

    2 Top Biotech Stocks to Buy for the Long Haul

    The healthcare industry is a great place to start. Let's examine two biotechs that seem to be able to do that: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP). Gilead Sciences is a leader in the market for HIV drugs although the company has recently faced some headwinds in this space.